echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dongyangguang: Application for drug registration of insulin aspart injection has been accepted

    Dongyangguang: Application for drug registration of insulin aspart injection has been accepted

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 1, Dongyang Sunshine issued an announcement stating that its holding subsidiary Yichang Dongyang Sunshine Yangtze River Pharmaceutical Co.


    Insulin aspart is a human insulin analogue.


    According to the data reported by the International Diabetes Federation in 2019, the number of diabetic patients in mainland China is about 116 million, and the incidence rate among people aged 20-79 is about 10.


    So far, Dongyang Sunshine Insulin Aspart Injection has invested approximately RMB 68,618,000 in research and development.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.